---
figid: PMC9576967__CCR3-10-e6392-g002
figtitle: 'Cancer patients and targeted therapy during COVID‐19 pandemic: A descriptive
  case series study'
organisms:
- NA
organisms_ner:
- Danio rerio
- Homo sapiens
pmcid: PMC9576967
filename: CCR3-10-e6392-g002.jpg
figlink: /pmc/articles/PMC9576967/figure/ccr36392-fig-0001/
number: F1
caption: COVID‐19 activates the cytokine release pathway through the ACEII receptor,
  Ibratinib, Nivolumab, and Ruxolitinib inhibit cytokine through the inhibit of BTK,
  PD‐L1 and JAK2 receptor, respectively. ACEII, angiotensin‐converting enzyme II;
  BTK, Bruton's tyrosine kinase; JAK2, Janus Kinase II; PD‐L1, Programmed death‐ligand
  1.
papertitle: 'Cancer patients and targeted therapy during COVID‐19 pandemic: A descriptive
  case series study.'
reftext: Kasra Khodadadi, et al. Clin Case Rep. 2022 Oct;10(10):e6392.
year: '2022'
doi: 10.1002/ccr3.6392
journal_title: Clinical Case Reports
journal_nlm_ta: Clin Case Rep
publisher_name: John Wiley and Sons Inc.
keywords: case series | COVID‐19 | immunotherapy | malignant disease | targeted therapy
automl_pathway: 0.9251164
figid_alias: PMC9576967__F1
figtype: Figure
redirect_from: /figures/PMC9576967__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9576967__CCR3-10-e6392-g002.html
  '@type': Dataset
  description: COVID‐19 activates the cytokine release pathway through the ACEII receptor,
    Ibratinib, Nivolumab, and Ruxolitinib inhibit cytokine through the inhibit of
    BTK, PD‐L1 and JAK2 receptor, respectively. ACEII, angiotensin‐converting enzyme
    II; BTK, Bruton's tyrosine kinase; JAK2, Janus Kinase II; PD‐L1, Programmed death‐ligand
    1.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - btk
  - tnfa
  - tnfb
  - ace
  - fgf8a
  - il6
  - si:ch211-241b2.5
  - il10
  - BTK
  - TNF
  - ACE
  - IL1B
  - IL6
  - CD274
  - IL10
---
